Abstract
A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.
| Original language | English |
|---|---|
| Pages (from-to) | 382-386 |
| Number of pages | 5 |
| Journal | Case Reports in Oncology |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - May 1 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
Cite this
A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab. / Kasagi, Yuta; Oki, Eiji; Ando, Koji; Kimura, Yasue; Ikegami, Toru; Saeki, Hiroshi; Morita, Masaru; Kusumoto, Tetsuya; Maehara, Yoshihiko.
In: Case Reports in Oncology, Vol. 6, No. 2, 01.05.2013, p. 382-386.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab
AU - Kasagi, Yuta
AU - Oki, Eiji
AU - Ando, Koji
AU - Kimura, Yasue
AU - Ikegami, Toru
AU - Saeki, Hiroshi
AU - Morita, Masaru
AU - Kusumoto, Tetsuya
AU - Maehara, Yoshihiko
PY - 2013/5/1
Y1 - 2013/5/1
N2 - A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.
AB - A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.
UR - http://www.scopus.com/inward/record.url?scp=84885577256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885577256&partnerID=8YFLogxK
U2 - 10.1159/000353781
DO - 10.1159/000353781
M3 - Article
C2 - 23904849
AN - SCOPUS:84885577256
VL - 6
SP - 382
EP - 386
JO - Case Reports in Oncology
JF - Case Reports in Oncology
SN - 1662-6575
IS - 2
ER -